Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674661 · ClinicalTrials.gov registry record · Phase 3
Corneal Collagen Cross-Linking for Ectasia (CXL)
A Phase 3 study of Ectasia, sponsored by Glaukos Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 130
- Enrollment target
- 10
- Study locations
NCT00674661: Completed Phase 3 study of Ectasia, sponsored by Glaukos Corporation.
NCT00674661 is a Phase 3 study of Ectasia that has completed, run by Glaukos Corporation. The registered enrollment target is 130 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00674661, a Phase 3 study of Ectasia, has completed, sponsored by Glaukos Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 130 participants
- Enrollment target
- 10
- Study locations
Study Summary
Prospective, randomized multicenter study to determine the safety and effectiveness of performing corneal collagen cross-linking (CXL) using riboflavin and UVA light in eyes with ectasia after refractive surgery.
Primary Outcome
The primary efficacy parameter was corneal curvature, as measured by maximum keratometry (Kmax) in the study eyes. Study success was defined as a difference of ≥1 D in the mean change in Kmax from baseline to 12 months between the CXL group and control group. Keratometry was measured manually and by pentacam.
Conditions Studied
Interventions
- DRUG riboflavin ophthalmic solution
- DEVICE UVA Irradiation
Study Locations (10)
California
- Shiley Eye Center - La Jolla
- Gordon -Weiss Vision Institute - San Diego
New York
- Edward Harkness Eye Institute at Columbia University Medical Center - New York
- Ophthalmic Consultants of Long Island - Rockville Centre
Florida
- Center for Excellence in Eye Care - Miami
Indiana
- Price Vision Group - Indianapolis
Kansas
- Durrie Vision - Kansas City
Maryland
- Wilmer Eye Institute at Johns Hopkins University - Baltimore
Minnesota
- Minnesota Eye Consultants - Minneapolis
New Jersey
- Cornea & Laser Eye Institute; Hersh Vision Group - Teaneck
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
What the finished NCT00674661 record still lists
NCT00674661 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Ectasia appearing as the primary indexed condition, and to 2 interventions - of which riboflavin ophthalmic solution is the first listed.
NCT00674661 lists 10 locations in 8 states (California, New York, Florida).
Frequently Asked Questions
What is clinical trial NCT00674661 about?
NCT00674661 is a clinical study titled "Corneal Collagen Cross-Linking for Ectasia (CXL)". Prospective, randomized multicenter study to determine the safety and effectiveness of performing corneal collagen cross-linking (CXL) using riboflavin and UVA light in eyes with ectasia after refractive surgery.
What is the current status of trial NCT00674661?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 130 participants. The study started on 2007-12. Estimated completion is 2011-11.
What conditions does trial NCT00674661 study?
This clinical trial studies the following conditions: Ectasia.
What interventions are being tested in trial NCT00674661?
The interventions under investigation include: riboflavin ophthalmic solution (DRUG), UVA Irradiation (DEVICE).
Who is sponsoring clinical trial NCT00674661?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00674661 being conducted?
This trial has 10 study locations across California, Florida, Indiana, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ectasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00674661's enrollment target sits among peer trials
130 1594th of 2000 higher than 404 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia